Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients

The objective of this study is to detect the evidence on the immune response following acute SARS-CoV-2 infections. the study will report the profile of IgG specific antibodies levels to SARS-CoV-2 infection found in recovered coronavirus disease (COVID-19) patients after infection for both symptomatic and asymptomatic patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

16 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag University Hospital

Sohag, Egypt

About this study

A total of 30 COVID-19 patients for the study will be enrolled. All the patients enrolled were confirmed to be infected with SARS-CoV-2 by RT-PCR assay for nasal and pharyngeal swab specimens.

For the study, serum samples of the 30 patients will be collected and will be investigated for the detection rate for immunoglobulin G (IgG). The first sample will be collected 2 weeks after the second negative RT-PCR assay for nasal and pharyngeal swab specimens and 6 samples will be collected after that for 6 months later; one serum sample tested every month for 6 months after.

The following questions will be addressed:-

What proportion of confirmed cases develops specific IgG antibodies to SARS-CoV-2?
How long is the duration of detection of serum IgG antibodies and antibody titres over time following infection with SARS-CoV-2?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with recent COVID- 19 infection(2 weeks after the second negative RT-PCR assay)

Exclusion criteria

patients on immune-suppressive therapy
patients with immunological disease

Treatment and study plan

Primary outcomes

rising titre of IGg antibodies

Time frame: first month

it's expected to have COVID-19 antibodies within 1month of infection the antibody titre expected to rise the fall to a lower levels

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Acronym: COVID-19

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Jul 23, 2020
Registry last updated: May 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed